ES2177922T3 - Metodo de valoracion la quimioterapia de pacientes hiv-positivos basado en la sensibilidad fenotipica a los farmacos de las cepas de hiv delpaciente. - Google Patents

Metodo de valoracion la quimioterapia de pacientes hiv-positivos basado en la sensibilidad fenotipica a los farmacos de las cepas de hiv delpaciente.

Info

Publication number
ES2177922T3
ES2177922T3 ES97900712T ES97900712T ES2177922T3 ES 2177922 T3 ES2177922 T3 ES 2177922T3 ES 97900712 T ES97900712 T ES 97900712T ES 97900712 T ES97900712 T ES 97900712T ES 2177922 T3 ES2177922 T3 ES 2177922T3
Authority
ES
Spain
Prior art keywords
hiv
chemical
sensitivity
data
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97900712T
Other languages
English (en)
Inventor
Bethune Marie-Pierre De
Kurt Hertogs
Rudi Pauwels
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virco BVBA
Original Assignee
Virco BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virco BVBA filed Critical Virco BVBA
Application granted granted Critical
Publication of ES2177922T3 publication Critical patent/ES2177922T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UN METODO PARA EL MANEJO DE LA QUIMIOTERAPIA ANTI-VIH DE PACIENTES QUE SON VIH POSITIVOS QUE COMPRENDE LA TRANSFECCION DE UNA LINEA CELULAR SUSCEPTIBLE A LA INFECCION DEL VIH CON UNA SECUENCIA, PREFERENTEMENTE AQUELLA QUE CODIFICA PARA EL RT Y LA PROTEASA, PROCEDENTE DEL GEN POL DEL VIH OBTENIDO DE UN PACIENTE Y UNA CONSTRUCCION DE ADN DEL VIH DEL CUAL HA SIDO DELECIONADA LA SECUENCIA, EL CULTIVO DE LAS CELULAS TRANSFECTADAS DE TAL FORMA QUE SE CREE UN STOCK DE VIRUS QUIMERICOS, LA VALORACION DE LA SENSIBILIDAD FENOTIPICA DE LOS VIRUS QUIMERICOS HACIA UN INHIBIDOR DE LA ENZIMA CODIFICADA POR EL GEN POL DEL VIH Y LA ASIGNACION A ESTA DE UN VALOR, LA CONSTRUCCION DE UN CONJUNTO DE DATOS QUE COMPRENDE EL VALOR PARA LA SENSIBILIDAD DEL VIRUS QUIMERICO Y EL CORRESPONDIENTE VALOR PARA UNA CEPA DE TIPO SALVAJE QUIMERICA DEL VIH, LA REPETICION DE LA VALORACION DE LA SENSIBILIDAD PARA AL MENOS OTROS DOS INHIBIDORES Y LA CONSTRUCCION EN TOTAL DE AL MENOS TRES CONJUNTOS DE DATOS DE ESTE TIPO, LA REPRESENTACION DE LOS CONJUNTOS DE DATOS EN GRAFICOS BI O TRIDIMENSIONALES, A PARTIR DE LOS CUALES SE PUEDE EXTRAER QUE LA DIFERENCIA ENTRE LAS SENSIBILIDADES QUIMERICAS Y DE TIPO SALVAJE EN EL CASO DE CADA CONJUNTO DE DATOS PROPORCIONA UNA MEDICION VISUAL DE LA RESISTENCIA DEL STOCK QUIMERICO AL TRATAMIENTO MEDIANTE EL INHIBIDOR EN CUESTION Y LA SELECCION DEL INHIBIDOR(ES) OPTIMO(S) EN BASE A LA REPRESENTACION GRAFICA DE LAS RESISTENCIAS A MEDIR. EL METODO PROPORCIONA INFORMACION FENOTIPICA A GRAN ESCALA SOBRE LOS PACIENTES INDIVIDUALES INFECTADOS CON VIH DE FORMA RAPIDA Y ECONOMICA. EL METODO ES APLICABLE A TODOS LOS REGIMENES QUIMIOTERAPEUTICOS DISPONIBLES ACTUALMENTE Y SE ESPERA QUE SE PUEDA APLICAR IGUALMENTE A LOS FUTUROS REGIMENES QUIMIOTERAPEUTICOS.
ES97900712T 1996-01-26 1997-01-24 Metodo de valoracion la quimioterapia de pacientes hiv-positivos basado en la sensibilidad fenotipica a los farmacos de las cepas de hiv delpaciente. Expired - Lifetime ES2177922T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96200175 1996-01-26

Publications (1)

Publication Number Publication Date
ES2177922T3 true ES2177922T3 (es) 2002-12-16

Family

ID=8223611

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97900712T Expired - Lifetime ES2177922T3 (es) 1996-01-26 1997-01-24 Metodo de valoracion la quimioterapia de pacientes hiv-positivos basado en la sensibilidad fenotipica a los farmacos de las cepas de hiv delpaciente.

Country Status (21)

Country Link
US (3) US6221578B1 (es)
EP (1) EP0877937B1 (es)
KR (1) KR100495690B1 (es)
CN (2) CN1991365A (es)
AT (1) ATE217971T1 (es)
AU (1) AU717755B2 (es)
BG (1) BG102710A (es)
BR (1) BR9707204A (es)
CZ (1) CZ292899B6 (es)
DE (1) DE69712731T2 (es)
ES (1) ES2177922T3 (es)
HU (1) HU226203B1 (es)
IL (1) IL125442A (es)
IS (1) IS4799A (es)
NO (1) NO321329B1 (es)
NZ (1) NZ325912A (es)
PL (1) PL186473B1 (es)
SK (1) SK283878B6 (es)
TR (1) TR199801443T2 (es)
WO (1) WO1997027480A1 (es)
ZA (1) ZA97669B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2123065T3 (es) 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
US20030220276A1 (en) * 1995-05-16 2003-11-27 Opendra Narayan HIV vaccine and method of use
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US20070010471A1 (en) * 1997-05-02 2007-01-11 Opendra Narayan HIV DNA vaccine
CA2298102A1 (en) * 1997-07-30 1999-02-11 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
NZ508834A (en) * 1998-05-26 2004-06-25 Virologic Inc Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy
ES2246859T3 (es) 1999-05-28 2006-03-01 Virco Bvba Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos.
US6800437B1 (en) 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
EP1109019A1 (en) * 1999-12-15 2001-06-20 BioStrands S.r.l. Method to evaluate the sensitivity of HIV variants to drugs able to inhibit the HIV protease
WO2001057245A2 (en) * 2000-02-04 2001-08-09 K.U.Leuven Research & Development Hiv-1 resistance assay
GB0009374D0 (en) * 2000-04-14 2000-05-31 Glaxo Group Ltd Phenotyping assay and reagents therefor
ATE526423T1 (de) 2000-04-18 2011-10-15 Virco Bvba Verfahren zum messen des medikamentenwiderstands gegen hcv
US6800463B1 (en) * 2000-04-20 2004-10-05 Virco Bvba Method for mutation detection in HIV-1 using pol sequencing
AU2001256318B8 (en) * 2000-04-20 2007-03-22 Virco Bvba Method for mutation detection in HIV using pol sequencing
US6582901B2 (en) * 2000-04-26 2003-06-24 Bruce K. Patterson Cell specific anti-viral drug susceptibility test using tagged permissive target cells
US7058616B1 (en) 2000-06-08 2006-06-06 Virco Bvba Method and system for predicting resistance of a disease to a therapeutic agent using a neural network
CA2411401A1 (en) * 2000-06-12 2001-12-20 Virologic, Inc. Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
US6582920B2 (en) * 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
JP4264256B2 (ja) * 2000-10-20 2009-05-13 ビルコ・ビーブイビーエイ 治療に対する耐性を予測するための生物学的カット−オフ値の確立
EP1356082A2 (en) * 2000-10-20 2003-10-29 Virco Bvba Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
EP1283272B1 (en) * 2001-08-08 2013-11-13 Janssen R&D Ireland Methods and means for assessing HIV envelope inhibitor therapy
US6958211B2 (en) * 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
WO2003040390A2 (en) 2001-11-08 2003-05-15 Tibotec Pharmaceuticals Ltd. Protease assay for therapeutic drug monitoring
EP1520247B1 (en) 2002-07-01 2009-05-27 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
DE60321466D1 (de) 2002-07-01 2008-07-17 Tibotec Pharm Ltd Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
CA2557790A1 (en) 2004-03-02 2005-09-15 Virco Bvba Estimation of clinical cut-offs
AU2006323930B2 (en) 2005-12-07 2012-06-21 Janssen Sciences Ireland Uc Methods, plasmid vectors and primers for assessing HIV viral fitness
US20100009341A1 (en) * 2006-04-14 2010-01-14 Inky Paul Madeleine De Baere Methods and means for assessing hiv gag/protease inhibitor therapy
CA2688278A1 (en) 2007-05-25 2008-12-04 Tibotec Pharmaceuticals New mutational profile in hiv-1 gag cleavage site correlated with phenotypic drug resistance
EP2342363B1 (en) * 2008-10-06 2015-06-10 Janssen Diagnostics BVBA Method for determining drug resistance mutations in any of the non-structural protein regions ns3 to ns5b of hepatitis c virus (hcv) for genotypes 1 to 6
US20120064514A1 (en) * 2009-05-12 2012-03-15 Virco Bvba Hiv-1-c resistance monitoring
CN107085093B (zh) * 2017-03-24 2019-06-21 西藏诺迪康药业股份有限公司 重组人白细胞介素1受体拮抗剂滴眼液生物学活性的检测方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875396A (en) 1973-11-12 1975-04-01 Illuminite Corp Illuminated clipboard
US4675147A (en) * 1983-04-06 1987-06-23 Westinghouse Electic Corp. Generating an integrated graphic display of the safety status of a complex process plant
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
IL94482A (en) 1989-05-25 2003-09-17 Univ Duke Transdominant repressor mutant of retroviral protein, dna encoding the protein and process for their preparation and use thereof
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
JPH05148202A (ja) * 1991-04-10 1993-06-15 Tsumura & Co 新規な化合物およびその医薬としての用途
AU4248593A (en) 1992-05-14 1993-12-13 Mark Holodniy Polymerase chain reaction assays for monitoring antiviral therapy
US5733720A (en) 1992-06-18 1998-03-31 Washington University Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor
KR100300932B1 (ko) 1992-07-06 2001-10-22 조이스 브린톤 리포터유전자에융합된세균의스트레스프로모터를이용하여독성을측정하는방법및진단키트
US5344846A (en) 1992-12-30 1994-09-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells
US5591579A (en) 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
US6063562A (en) 1994-09-16 2000-05-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
CA2232086A1 (en) 1995-09-15 1997-04-03 Samir Chachoua Method for the identification and therapeutic use of disease-associated organisms, elements and forces
US5885806A (en) * 1995-11-28 1999-03-23 The Johns Hopkins University School Of Medicine Methods to prepare conditionally replicating viral vectors
US5837464A (en) 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
EP0852626B1 (en) 1996-01-29 2002-04-03 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US5945276A (en) 1996-04-10 1999-08-31 Signal Pharmaceuticals, Inc. Reporter cell line system for detecting cytomegalovirus and identifying modulators of viral gene expression
US5939253A (en) 1996-04-26 1999-08-17 Diagnostic Hybrids, Inc. Compositions and methods for detecting viral infection
DE69804446T3 (de) 1997-04-07 2006-08-24 Bioimage A/S Verfahren um quantitativen informationen über einflüsse auf zelluläre reaktionen zu entnehmen
US6365347B1 (en) 1997-04-11 2002-04-02 The Regents Of The University Of California Method for identifying disruptors of biological pathways using genetic selection
WO1998059074A1 (en) 1997-06-23 1998-12-30 Emory University Human immunodeficiency viruses causing aids in a nonhuman primate
US5976813A (en) 1997-12-12 1999-11-02 Abbott Laboratories Continuous format high throughput screening

Also Published As

Publication number Publication date
HU226203B1 (en) 2008-06-30
NZ325912A (en) 1999-01-28
US6528251B2 (en) 2003-03-04
US20020042679A1 (en) 2002-04-11
NO983300L (no) 1998-09-25
US6221578B1 (en) 2001-04-24
EP0877937A1 (en) 1998-11-18
IL125442A0 (en) 1999-03-12
HUP9902618A3 (en) 2001-04-28
CZ292899B6 (cs) 2003-12-17
ZA97669B (en) 1998-06-25
IL125442A (en) 2002-03-10
PL328069A1 (en) 1999-01-04
KR19990082027A (ko) 1999-11-15
HUP9902618A2 (hu) 1999-12-28
AU1316897A (en) 1997-08-20
CZ233598A3 (cs) 1999-06-16
NO321329B1 (no) 2006-04-24
US20030152917A1 (en) 2003-08-14
SK283878B6 (sk) 2004-04-06
BG102710A (en) 1999-03-31
BR9707204A (pt) 1999-12-28
EP0877937B1 (en) 2002-05-22
SK100298A3 (en) 1999-02-11
WO1997027480A1 (en) 1997-07-31
TR199801443T2 (xx) 1998-10-21
DE69712731T2 (de) 2003-02-06
ATE217971T1 (de) 2002-06-15
IS4799A (is) 1998-07-20
PL186473B1 (pl) 2004-01-30
NO983300D0 (no) 1998-07-16
CN1209875A (zh) 1999-03-03
DE69712731D1 (de) 2002-06-27
AU717755B2 (en) 2000-03-30
KR100495690B1 (ko) 2005-11-08
CN1991365A (zh) 2007-07-04

Similar Documents

Publication Publication Date Title
ES2177922T3 (es) Metodo de valoracion la quimioterapia de pacientes hiv-positivos basado en la sensibilidad fenotipica a los farmacos de las cepas de hiv delpaciente.
Lake et al. Evolution of parasitism: kinetoplastid protozoan history reconstructed from mitochondrial rRNA gene sequences.
Liszewski et al. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR
Peterson et al. The A/P axis in echinoderm ontogeny and evolution: evidence from fossils and molecules
Esselman et al. RAPD marker diversity within and divergence among species of Dendroseris (Asteraceae: Lactuceae)
Schmitz et al. Molecular studies on the genus Eumeces Wiegmann, 1834: phylogenetic relationships and taxonomic implications
Escalera‐Zamudio et al. On the classification and evolution of endogenous retrovirus: human endogenous retroviruses may not be ‘human’after all
EE200100195A (et) Vähemalt ühe nukleiinhappe amplifitseerimismeetod, erinevate nukleiinhappe matriitside hulk, tahke maatriks ja nende kasutamine ning komplekt
Jackson et al. Mitochondrial DNA genetic diversity among four ethnic groups in Sierra Leone
Rao et al. Variability of human linkage data
ATE304059T1 (de) Methode zur genvervielfältigung
ATE541924T1 (de) Selektion und isolierung lebender zellen unter verwendung rna-bindender sonden
ATE107705T1 (de) Test zur feststellung der empfänglichkeit für dns-assoziierte krankheiten.
Luo et al. Morphology, ontogeny, and molecular phylogeny of two freshwater species of Deviata (Ciliophora, Hypotrichia) from southern China
Song et al. Re‐Evaluation on the Diversity of the Polyphyletic Genus Metaurostylopsis (Ciliophora, Hypotricha): Ontogenetic, Morphologic, and Molecular Data Suggest the Establishment of a New Genus Apourostylopsis ng
Froufe et al. Comparative mtDNA sequence (control region, ATPase 6 and NADH‐1) divergence in Hucho taimen (Pallas) across four Siberian river basins
DE60213406D1 (de) Pharmakologische anwendungen von mitochondriellen dna assays
ATE415491T1 (de) Oligonucleotide zur markierung von oligonukleotidsonden und proteine
Pacak et al. RAPD technique for taxonomic studies of Pellia epiphylla‐complex (Hepaticae, Metzgeriales)
Dodge et al. Comparison of phylogenies derived from two molecular data sets in the avian genera Pipilo and Spizella
Takenouchi et al. Defective human T‐lymphotropic virus type 1 provirus in asymptomatic carriers
Colyer et al. Channel catfish virus: use of nucleic acids in studying viral relationships
BR9605926A (pt) Utilização de um material viral e retroviral de um fragmento de nucleotideo de um indicador especifico de uma sonda de um agente patógeno e/ou infeccioso de uma associação de fragmentos nucleotideos processo para a obtenção de um primeiro agente patogeno e/ou infeccioso indicador especifico para a ampliação por plimerização de rna ou dna de um material viral e sonda suscetivel de hibridizar especificamente com rna ou dna de um material viral
Van Pham et al. Sphenomorphus tamchucensis sp. nov.(Squamata, Scincidae), a new skink from Vietnam
Knoll The Origin and Early Diversification of Land Plants: A Cladistic Study